摘要
血睾屏障(BTB)是男性体内最重要的供血障碍之一,它将精曲小管的上皮细胞,即睾丸的功能单位——精子产生的地方分成基地和顶部的隔间。功能上,BTB为减数分裂I / II和精子细胞发育提供了一个独特的微环境,其发生在心室中。远离宿主的免疫系统有助于睾丸的免疫状态。然而,BTB也是开发男性避孕药(例如,adjudin)的主要障碍,对生殖细胞产生影响,如通过破坏精子与Sertoli细胞的粘附,从而使生殖细胞从睾丸中脱落。除了在BTB中紧密黏附的Sertoli细胞可制约间质微血管腔部分,药物转运蛋白如P-糖蛋白和多药耐药相关蛋白1(MRP1),也存在处于睾丸之外的活性药物,从而限制了药物的生物利用度。在药物制剂的研究进展中,如药物颗粒的微细化(<50μm)和ß环糊精药物微粒化的共同粉碎已经通过大幅度的提高溶解度提高了避孕药的生物活性。在此,我们讨论药物制剂的进展,以adjudin为例。也强调了纳米技术将adjudin发送到多药磁性介质二氧化硅纳米颗粒的顶层去的用法。这些技术的进步,将大大提高我们的能力,为男性开发有效的非激素避孕药。
关键词: 睾丸;男性避孕;血睾屏障;adjudin;纳米技术。
Current Medicinal Chemistry
Title:Effective Delivery of Male Contraceptives Behind the Blood-Testis Barrier (BTB) – Lesson from Adjudin
Volume: 23 Issue: 7
Author(s): Haiqi Chen, Dolores D. Mruk, Weiliang Xia, Michele Bonanomi, Bruno Silvestrini, Chuen-Yan Cheng
Affiliation:
关键词: 睾丸;男性避孕;血睾屏障;adjudin;纳米技术。
摘要: The blood-testis barrier (BTB) is one of the tightest blood-tissue barriers in the mammalian body. It divides the seminiferous epithelium of the seminiferous tubule, the functional unit of the testis, where spermatogenesis takes place, into the basal and the adluminal (apical) compartments. Functionally, the BTB provides a unique microenvironment for meiosis I/II and post-meiotic spermatid development which take place exclusively in the apical compartment, away from the host immune system, and it contributes to the immune privilege status of testis. However, the BTB also poses major obstacles in developing male contraceptives (e.g., adjudin) that exert their effects on germ cells in the apical compartment, such as by disrupting spermatid adhesion to the Sertoli cell, causing germ cell exfoliation from the testis. Besides the tight junction (TJ) between adjacent Sertoli cells at the BTB that restricts the entry of contraceptives from the microvessels in the interstitium to the adluminal compartment, drug transporters, such as P-glycoprotein and multidrug resistance-associated protein 1 (MRP1), are also present that actively pump drugs out of the testis, limiting drug bioavailability. Recent advances in drug formulations, such as drug particle micronization (<50 μm) and co-grinding of drug particles with ß-cyclodextrin have improved bioavailability of contraceptives via considerable increase in solubility. Herein, we discuss development in drug formulations using adjudin as an example. We also put emphasis on the possible use of nanotechnology to deliver adjudin to the apical compartment with multidrug magnetic mesoporous silica nanoparticles. These advances in technology will significantly enhance our ability to develop effective non-hormonal male contraceptives for men.
Export Options
About this article
Cite this article as:
Haiqi Chen, Dolores D. Mruk, Weiliang Xia, Michele Bonanomi, Bruno Silvestrini, Chuen-Yan Cheng , Effective Delivery of Male Contraceptives Behind the Blood-Testis Barrier (BTB) – Lesson from Adjudin, Current Medicinal Chemistry 2016; 23 (7) . https://dx.doi.org/10.2174/0929867323666160112122724
DOI https://dx.doi.org/10.2174/0929867323666160112122724 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Effect of TRAF1 on Phenotypic Changes Of Kupffer Cells In Liver Transplantation Ischemic-Reperfusion
Current Pharmaceutical Biotechnology S-nitrosation/Denitrosation in Cardiovascular Pathologies: Facts and Concepts for the Rational Design of S-nitrosothiols
Current Pharmaceutical Design Update to Medicinal Chemistry of Nicotinamide in the Treatment of Ischemia and Reperfusion
Medicinal Chemistry Reviews - Online (Discontinued) Is the Deficiency of Vitamin B12 Related to Oxidative Stress and Neurotoxicity in Parkinsons Patients?
CNS & Neurological Disorders - Drug Targets Pharmacokinetics of Picroside I, II, III, IV in Rat Plasma by UPLCMS/ MS
Current Pharmaceutical Analysis Application of Carbon Nanotubes In Drug Delivery of Non-cancerous Diseases: A Review
Current Pharmaceutical Design Gut Microbiota and Cardiovascular Disease: Symbiosis Versus Dysbiosis
Current Medicinal Chemistry Editorial: (Thematic Issue: Novel Strategies for Cardiac Repair Post-Myocardial Infarction)
Current Pharmaceutical Design Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Cellular Actions of Nesfatin-1 on Hypothalamic and Medullary Neurons
Current Pharmaceutical Design Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Omega-3 Polyunsaturated Fatty Acid Derived Lipid Mediators and their Application in Drug Discovery
Current Medicinal Chemistry Daboia russelli Venom Hyaluronidase: Purification, Characterization and Inhibition by β-3-(3-Hydroxy-4-Oxopyridyl) α-Amino-Propionic Acid
Current Topics in Medicinal Chemistry Ischemic Post-Conditioning Partially Reverses Cell Cycle Reactivity Following Ischemia/Reperfusion Injury: A Genome-Wide Survey
CNS & Neurological Disorders - Drug Targets Ocular Vascular Involvement in the Rheumatic Diseases
Current Rheumatology Reviews An Old Drug with a New Purpose: Cardiovascular Actions of Acetaminophen (Paracetamol)
Current Drug Targets - Cardiovascular & Hematological Disorders Pharmacological Management of No Reflow During Percutaneous Coronary Intervention
Current Vascular Pharmacology Medicinal Plants in Neurodegenerative Diseases: Perspective of Traditional Persian Medicine
Current Drug Metabolism